Italian (good) : Omega CRO - Ankara Guniz Sok. 32/ Kavaklidere Tel: / Fax:

Transcription

1 NAME : Murat Hayran, M.D. DATE OF BIRTH : 3th April 1960 PLACE OF BIRTH NATIONALITY FOREIGN LANGUAGES ADDRESS : Edirne, Turkey. : Turkish : English (good) Italian (good) : Omega CRO - Ankara Guniz Sok. 32/ Kavaklidere Tel: / Fax: EDUCATION : Muharrem Hasbi High School, Balıkesir, Turkey : Doctor of Medicine, : Resident, Department of Microbiology : Fellow, Department of Medicine, Section of Infectious Diseases MEDICAL LICENSURE 1984 : Medical Doctor. Hacettepe University Ankara 1991 : Certified Clinical Microbiologist 1994 : Assistant Professor in Infectious Diseases 1995 : Associate Professor in Infectious Diseases and Clinical Microbiology CV of Murat Hayran 1 / 8

2 HONORS AND AWARDS 1977 : Valedictorian, Class of 400, Muharrem Hasbi High School, Balìkesir, Turkey : The Italian Culture Association Scholar for Linguistic Course 1991 : Jaycees Award for Science and Technical Development : Scientific Award Hacettepe University : The British Council Scholar for Scientific Research : George Gee Jackson Award, Hacettepe University Department of Medicine. Section of Infectious Diseases, Ankara. CV of Murat Hayran 2 / 8

3 EXPERIENCE : Practicing Physician, Turkish Electricity Company, Bolu, Turkey : Local Chief of Medical Service in Italian SAIPEM SpA. Turkey Section of Iraq-Turkey 2nd Pipeline Project Mardin, Turkey : Resident Department of Microbiology, : Research fellow, Department of Medicine, Section of Infectious Diseases : Consultant, Department of Medicine, Section of Infectious Diseases : Research Coordinator : Founder/Manager Omega CRO : Founder/President Association of Contract Research Organization Companies Istanbul, Turkey : Co-founder/Director ACTUS Health Policies and Management Center Istanbul, Turkey CV of Murat Hayran 3 / 8

4 COMPLETED MAJOR PROJECTS BEFORE OMEGA Subject: Clinical Presentation of Jaundice in Europe (EURICTERUS). Sponsor: European Union Biomed and Health Research Programme Role in the project: Data gatherer Project No: MR Subject: Seroepidemiology of BK virus in Turkey. Sponsor: Turkish Scientific and Technical Research Council. Role in the project: Research associate. Project No: TAG Subject: Use of PCR in the diagnosis of tuberculosis and HPV. Sponsor: Institute of Govermental Planning. Role in the project: Research associate Project No: 91K Subject: Relation between bacterial translocation and obstructive jaundice and hiperbilirubinemia. Sponsor: Turkish Scientific and Technical Research Council. Role in the project: Co-investigator Project No: TAG Subject: Epidemiologic antibiotic resistance mapping of Turkey. Sponsor: Turkish Scientific and Technical Research Council. Role in the project: Data manager. Project No: TAG Subject: Phase III trial on Azythromycin treatment in patients with lower respiratory infections. Sponsor: Pfizer International Role in the project: Co-investigator Subject: One day vs three day ofloxacin treatment in the treatment of acute bacterial gastroenteritis. Sponsor: Hoechst International Role in the project: Data manager Subject: Definition of methicillin resistance pattern by PCR in staphylococci isolated from different hospitals in Turkey. Sponsor: Turkish Scientific and Technical Research Council. Role in the project: Research associate. Project No: TAG Subject: Multi-center Phase III trial on Meropenem treatment in febrile neutropenic patients. Sponsor: Zeneca Turkey. Role in the project: Data manager CV of Murat Hayran 4 / 8

5 Subject: Phase III trial on Cp99,219 (Trovafloxacin) treatment in patients with urinary tract infections. Sponsor: Pfizer International. Role in the project: Co-investigator Subject: Multi-center Phase IIIb trial on Cefepime treatment in febrile neutropenic patients. Sponsor: Bristol-Myers-Squibb Turkey. Role in the project: Co-investigator Subject: WHO network on antimicrobial resistance monitoring: WHONET Role in the project: Data collection from invited laboratories in Turkey. COMPLETED MAJOR PROJECTS AT OMEGA 873 projects in total (105 of them were international studies) 300 Clinical Trials 25 Phase II Trials 125 Phase III Trials 43 Phase IIIB Trials 107 Phase IV Trials 74 Observational Studies 54 Feasibility Studies 45 Medical Writing 37 Hospital-Based Practice Pattern Studies 36 Training Programmes 36 Statistical Consultancies 34 Postmarketting Surveilance Studies (PMSS) 31 Hospital-Based Pharmacoepidemiologic Studies 31 Hospital-Based Epidemiologic Surveys 27 Field-Based Epidemiologic Surveys 11 Clinical Study Consultancies 11 Laboratory Based Studies 10 Hospital-Based Pharmacoeconomics Studies 136 Other type of research studies CV of Murat Hayran 5 / 8

6 PUBLICATIONS 1. Unal S, Hayran M, Tuncer S, Gur D, Uzun O, Akova M, Akalin HE. Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Antimicrob Agents Chemother Dec;40(12): Akcan Y, Tuncer S, Hayran M, Sungur A, Unal S. PCR on disseminated tuberculosis in bone marrow and liver biopsy specimens: correlation to histopathological and clinical diagnosis. Scand J Infect Dis. 1997;29(3): Topeli A, Unal S, Hayran M, Akalin HE. Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis Jun;16(6): Yalcin AN, Hayran M, Unal S. Economic analysis of nosocomial infections in a Turkish university hospital. J Chemother Dec;9(6): Akhan SA, Hayran M. Treatment with beta-lactams and superinfection with Stenotrophomonas maltophilia: a historical cohort study could show us more. Clin Infect Dis Feb;26(2):532. No abstract available. 6. Arikan S, Akova M, Hayran M, Ozdemir O, Erman M, Gur D, Unal S. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis Apr;26(4): Celik I, Kars A, Guler N, Barista I, Tekuzman G, Ozyilkan O, Hayran M, Firat D. Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-hodgkin's lymphomas. Eur J Cancer Apr;34(5): No abstract available. 8. Kocagoz T, Hayran M, Kocagoz S. [A new rapid antibiotic susceptibility test for enteric bacteria using a color change method]. Mikrobiyol Bul. 1988;22(3): Turkish. 9. Us D, Hayran M. [Human B-lymphotropic virus (HBLV): human herpesvirus-6 (HHV-6)]. Mikrobiyol Bul Apr;23(2): Review. Turkish. 10. Sener B, Hayran M, Kocagoz T, Ustacelebi S. [The in vitro activity of ciprofloxacin against clinicallyisolated strains of Pseudomonas aeruginosa and comparison with some other antibiotics]. Mikrobiyol Bul Apr;24(2): Turkish. 11. Us D, Hayran M, Ustacelebi S. [New human polyomavirus; BK virus antibody levels in different age groups using the hemagglutination inhibition test]. Mikrobiyol Bul Apr;25(2): Turkish. 12. US D, Hayran M, Ustacelebi S. [New human polyomavirus: comparison of hemagglutination inhibition, ELISA and complement fixation tests for BK virus serology]. Mikrobiyol Bul Jul;25(3): Turkish. 13. Akova M, Akan H, Korten V, Biberoglu K, Hayran M, Unal S, Kars A, Kansu E. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents Sep;13(1): Akan OA, Ozalp M, Sener B, Hayran M, Baykal M. [Staphylococcal biotyping and the use of computers]. Mikrobiyol Bul Apr;26(2): Turkish. CV of Murat Hayran 6 / 8

7 15. Uzun O, Akalin HE, Hayran M, Unal S. Factors influencing prognosis in bacteremia due to gramnegative organisms: evaluation of 448 episodes in a Turkish university hospital. Clin Infect Dis Nov;15(5): Review. 16. Kocagoz T, Yilmaz E, Ozkara S, Kocagoz S, Hayran M, Sachedeva M, Chambers HF. Detection of Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified procedure. J Clin Microbiol Jun;31(6): Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother Sep;37(9): Uzun O, Hayran M, Akova M, Gur D, Akalin HE. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report. J Chemother Feb;6(1): Akova M, Akalin HE, Uzun O, Hayran M, Tekuzman G, Kansu E, Aslan S, Telatar H. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin Infect Dis Mar;18(3): Topeli A, Erdem Y, Yalcin AU, Oymak O, Hayran M, Yasavul U, Turgan C, Caglar S. Severe hypoglycemia in a patient with chronic renal failure due to amyloidosis. Nephron. 1996;72(2): Bascil N, Erdem Y, Yalcin AU, Hayran M, Haznedaroglu IC, Yasavul U, Turgan C, Caglar S. Evisceration of the eye in a renal transplant recipient with cytomegalovirus chorioretinitis. Am J Nephrol. 1996;16(4): No abstract available. 22. Barista I, Celik I, Gullu I, Hayran M, Akova M. Integrating the time factor into the definition of metastasis of unknown origin. J Natl Cancer Inst Jan 3;88(1):51. No abstract available. 23. Cakmakci M, Tirnaksiz B, Hayran M, Belek S, Gurbuz T, Sayek I. Effects of obstructive jaundice and external biliary diversion on bacterial translocation in rats. Eur J Surg Jul;162(7): Unal S, Hayran M, Tuncer S, Gur D, Uzun O, Akova M, Akalin HE. Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Antimicrob Agents Chemother Dec;40(12): Tuncer S, Hayran M, Akan O, Gur D, Akova M, Unal S. Native valve endocarditis with persistent embolization due to Neisseria mucosa. Clin Microbiol Infect Feb;3(1): No abstract available. 26. Topeli A, Unal S, Hayran M, Akalin HE. Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis Jun;16(6): Yalcin AN, Hayran M, Unal S. Economic analysis of nosocomial infections in a Turkish university hospital. J Chemother Dec;9(6): CV of Murat Hayran 7 / 8

8 28. Akhan SA, Hayran M. Treatment with beta-lactams and superinfection with Stenotrophomonas maltophilia: a historical cohort study could show us more. Clin Infect Dis Feb;26(2):532. No abstract available. 29. Arikan S, Akova M, Hayran M, Ozdemir O, Erman M, Gur D, Unal S. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis Apr;26(4): Akova M, Akan H, Korten V, Biberoglu K, Hayran M, Unal S, Kars A, Kansu E. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents Sep;13(1): Cetinkaya Y, Kocagoz S, Hayran M, Uzun O, Akova M, Gursu G, Unal S. Analysis of a mini-outbreak of methicillin-resistant Staphylococcus aureus in a surgical ward by using arbitrarily primedpolymerase chain reaction. J Chemother Apr;12(2): Cetinkaya Y, Akova M, Akalin HE, Ascioglu S, Hayran M, Uzuns O, Aksoyek S, Tokgozoglu L, Oto A, Kes S, Pasaoglu I, Unal S. A retrospective review of 228 episodes of infective endocarditis where rheumatic valvular disease is still common. Int J Antimicrob Agents Jul;18(1): Hayran M. Appropriate analysis and presentation of data is a must for good clinical practice. Acta Neurochir Suppl. 2002;83: CV of Murat Hayran 8 / 8